PORT HUENEME, CA--(Marketwire - June 22, 2010) - Stellar Biotechnologies, Inc. (
Known very well to researchers, scientists and immunology physicians, but practically unheard of by even sophisticated investors, Stellar's product, KLH (http://en.wikipedia.org/wiki/Keyhole_limpet_hemocyanin), is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is used in conjugate therapeutic vaccines and other biomedical products. A world leader in the production of KLH, Stellar maximizes the commercial impact of its Stellar KLH production platform and intellectual property, expanding the sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the rare keyhole limpet, and Stellar's technology for limpet maintenance, non-lethal extraction and refinement of the molecule differentiate it for growing research and pharmaceutical markets.
"Because of the unique properties of KLH, an expanding number of researchers and scientists in academia, biotech and Pharma are finding novel and amazing uses for it."
AIDS Discoverer & Chairman, Scientific Advisory Board, Andrew Saxon, M.D.
Darrell Brookstein, Stellar's Executive VP, said, "Many international pharma, biotech, vaccine and novel therapeutic companies, are working with KLH, and we believe using Stellar KLH and working closely with the scientists at Stellar makes a difference. Many are unfamiliar with how delicate the sustainability of the natural resource is or wrongly assume KLH is a manufactured protein. The oil environmental tragedy in the Gulf of Mexico highlights the need for companies to pay closer attention to reliability and availability of their key ingredient sources."
He added, "Our eventual, greatest successes as a corporation serving our shareholders' interests, will come from mutually beneficial associations and partnerships formed with other companies and institutions. With respect and flexibility, opportunities can be rewarding to both parties. We can help create advances in medicine and technology through relationships with scientists outside our confines. More crucial information, C-level appointments, and presentation materials will be added soon. Expect dynamic growth at the website over the next couple months. You are invited to return to www.StellarBiotechnologies.com often."
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
Contact:
Darrell Brookstein
Executive VP
dbrookstein@stellarbiotech.com
858-449-2523